C:\stnweb\Queries\5a.str





chain nodes :
7 8 10 18 19 20 21
ring nodes :
1 2 3 4 5 11 12 13 14 15 16 22 23 24 25 26 27
chain bonds :
2-7 4-8 5-10 10-14 11-18 18-19 19-20 20-21
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-12 11-16 12-13 13-14 14-15 15-16 22-23 22-27 23-24
24-25 25-26 26-27
exact/norm bonds :
2-3 2-7 3-4 4-8 11-18
exact bonds :
1-2 1-5 4-5 5-10 10-14 18-19 19-20 20-21
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16 22-23 22-27 23-24 24-25 25-26 26-27
isolated ring systems :
containing 1 : 11 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS

C:\stnweb\Queries\5.str





chain nodes :
7 8 10 20 21 22 23
ring nodes :
1 2 3 4 5 11 12 13 14 15 16 26 27 28 29 30 31
chain bonds :
2-7 4-8 5-10 10-14 11-20 20-21 21-22 22-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-12 11-16 12-13 13-14 14-15 15-16 26-27 26-31 27-28
28-29 29-30 30-31
exact/norm bonds :
2-3 2-7 3-4 4-8 11-20
exact bonds :
1-2 1-5 4-5 5-10 10-14 20-21 21-22 22-23
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16 26-27 26-31 27-28 28-29 29-30 30-31
isolated ring systems :
containing 1 : 11 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3   JAN 27   Source of Registration (SR) information in REGISTRY updated
                    and searchable
 NEWS  4   JAN 27   A new search aid, the Company Name Thesaurus, available in
                    CA/CAplus
 NEWS  5   FEB 05   German (DE) application and patent publication number format
                    changes
 NEWS  6   MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS  7   MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8   MAR 03   FRANCEPAT now available on STN
 NEWS  9   MAR 29   Pharmaceutical Substances (PS) now available on STN
 NEWS 10   MAR 29   WPIFV now available on STN
 NEWS 11   MAR 29   No connect hour charges in WPIFV until May 1, 2004
 NEWS 12   MAR 29   New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 13   APR 26   PROMT: New display field available
 NEWS 14   APR 26   FIPAT/IFIUDB/IFICDB: New super search and display field
                    available
 NEWS 15   APR 26   LITALERT now available on STN
 NEWS 16   APR 27   NLDB: New search and display fields available

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:40:09 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:40:15 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 APR 2004  HIGHEST RN 677274-15-6
DICTIONARY FILE UPDATES:  27 APR 2004  HIGHEST RN 677274-15-6
```

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
0 27 S 28

Page 1-A



Page 1-B



Page 2-A



Page 2-B



Page 3-A



Page 3-B
@23

@24
Page 3-C
VAR G1=27/28
REP G19=(1-2) 8-5 8-12
REP G20=(0-2) 16-15 16-17
VPA 18-22/23/24 S
NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS C AT 6
NSPEC IS C AT 7
NSPEC IS C AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS R AT 11
NSPEC IS R AT 12
NSPEC IS R AT 13
NSPEC IS R AT 14
NSPEC IS C AT 15
NSPEC IS C AT 16
NSPEC IS C AT 17
NSPEC IS C AT 18
NSPEC IS R AT 19
NSPEC IS R AT 20
NSPEC IS R AT 21
NSPEC IS R AT 22
NSPEC IS R AT 23
NSPEC IS R AT 24
NSPEC IS C AT 25
NSPEC IS C AT 26
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 8 15 16 17 18 27 28
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 9 5
NUMBER OF NODES IS 28

```
STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 16:41:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                              5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               5 TO      234

L2             5 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:41:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    175 TO ITERATE

100.0% PROCESSED     175 ITERATIONS                           112 ANSWERS
SEARCH TIME: 00.00.01

L3           112 SEA SSS FUL L1

=>
L4       STRUCTURE UPLOADED

=> s l4
SAMPLE SEARCH INITIATED 16:42:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                              4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               4 TO      200

L5             4 SEA SSS SAM L4

=> s l4 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:42:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    178 TO ITERATE

100.0% PROCESSED     178 ITERATIONS                           104 ANSWERS
SEARCH TIME: 00.00.01

L6           104 SEA SSS FUL L4

=> s l3 not l6
L7             8 L3 NOT L6

=> file hcaplus
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	311.68	311.89

FILE 'HCAPLUS' ENTERED AT 16:42:37 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l7
L8            2 L7

=> s l7/thu
              2 L7
         588726 THU/RL
L9            1 L7/THU
                  (L7 (L) THU/RL)

=> d l9, ibib abs fhitstr, 1
```

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:717892 HCAPLUS
DOCUMENT NUMBER: 128:3688
TITLE: Preparation of aryl(carboxamido)azoles and analogs as modulators of molecules with phosphotyrosine recognition units
INVENTOR(S): Andersen, Henrik Sune; Moller, Niels Peter Hundahl; Madsen, Peter
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740017	A2	19971030	WO 1997-DK166	19970417
WO 9740017	A3	19971211		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5958957	A	19990928	US 1997-842801		19970416
AU 9723813	A1	19971112	AU 1997-23813		19970417
JP 2000511883	T2	20000912	JP 1997-537609		19970417
ZA 9703349	A	19980120	ZA 1997-3349		19970418
US 5972978	A	19991026	US 1999-252883		19990219
US 6063800	A	20000516	US 1999-253443		19990219
US 6080770	A	20000627	US 1999-253419		19990219

PRIORITY APPLN. INFO.:

DK 1996-464	A	19960419
US 1996-22116P	P	19960717
US 1997-842801	A3	19970416
WO 1997-DK166	W	19970417

OTHER SOURCE(S): MARPAT 128:3688

AB R1ZR [R = NHSO3, CONHOH, azolyl, etc.; R1 = (un)substituted (un)substituted (hetero)aryl, (di)(alkyl)amino, etc.; Z = bond, alkylene, CONH, (alkyl)imino, etc.] were prepd. as modulators of mols. with phosphotyrosine recognition units, e.g., as protein tyrosine phosphatase inhibitors, (no data). Thus, Et 2-naphthalenecarboxylate was amidated by H2NNH2 and the product cyclocondensed with CS2 to give 5-(2-naphthyl)-1,3,4-oxadiazol-2(3H)-thione.

IT **198894-23-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl(carboxamido)azoles and analogs as modulators of mols. with phosphotyrosine recognition units)

RN 198894-23-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[difluoro[4-[2-[(5-methyl-2-pyridinyl)amino]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



CN 1429551	A	20030716	CN 2002-156128	20021206		
US 2003109553	A1	20030612	US 2003-340426	20030110		
PRIORITY APPLN. INFO.:			GB 1997-12857	A	19970618	
			GB 1998-6706	A	19980327	
			NZ 1998-501260	A1	19980615	
			WO 1998-EP3690	W	19980615	
			US 1999-446030	B1	19991215	
			US 2001-925394	B1	20010809	
			US 2002-99161	B1	20020313	

AB A method for the treatment and/or prophylaxis of diabetes mellitus, conditions assocd. with diabetes mellitus, and certain complications thereof, in a mammal which method comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer rosiglitazone (I) and a biguanide antihyperglycemic agent such as metformin. Pharmacokinetics of I and metformin administered alone or in combination are described. Formulations for prepg. tablets contg. I is presented.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> **s 128:3688/dn**
L2 1 128:3688/DN

=> **d l2, ibib abs fhitstr, 1**

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:717892 HCAPLUS
DOCUMENT NUMBER: **128:3688**
TITLE: Preparation of aryl(carboxamido)azoles and analogs as modulators of molecules with phosphotyrosine recognition units
INVENTOR(S): Andersen, Henrik Sune; Moller, Niels Peter Hundahl; Madsen, Peter
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740017	A2	19971030	WO 1997-DK166	19970417
WO 9740017	A3	19971211		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5958957	A	19990928	US 1997-842801	19970416
AU 9723813	A1	19971112	AU 1997-23813	19970417
JP 2000511883	T2	20000912	JP 1997-537609	19970417
ZA 9703349	A	19980120	ZA 1997-3349	19970418

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 72 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]difluoromethyl]- (9CI)
MF C24 H25 F2 N O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 72 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzaldehyde, 3-[([1,1'-biphenyl]-4-yloxy)methyl]- (9CI)
MF C20 H16 O2



We're sorry, your library's copies of this eBook are currently in use. Either try again later or use one the options below.

- View the Table of Contents of this title now
- Request to be notified when this title becomes available

eBook Details

Details and Viewing tips...

Polymorphism in Pharmaceutical Solids
Drugs and the Pharmaceutical Sciences ; V. 95



Viewing Options

View this eBook | Checkout for 4 Hours

Other Options

Add to My List | Email this Information

Title:	**Polymorphism in Pharmaceutical Solids** Drugs and the Pharmaceutical Sciences ; V. 95
Author:	Brittain, H. G.
Publication:	New York Marcel Dekker, Inc., 1999.
Product ID:	12783
eBook ISBN:	0585158290
ISBN:	0824702379
Subject:	Solid dosage forms. Polymorphism (Crystallography) Solvation. Hydration. Chemistry, Pharmaceutical. Molecular Structure. Crystallization.
Language:	English

Your Library

United States Patent And Trademark

Basic Search

Keyword

Search



IV. Kinetically Impaired Equilibria 58

A. Suspended Phase Transformations 58

B. Pressure-Temperature Relations Between Stable and Metastable Phases 60

V. Systems of Two Components 61

A. Solid/Vapor Equilibria 62

B. Solid/Liquid/Vapor Equilibria 68

C. Kinetically Impaired Equilibria 69

VI. Summary 70

References 70

I. Introduction To The Phase Rule

When considering questions of equilibria, one ordinarily thinks of chemical reactions taking place in a suitable medium. However, it is well known that a variety of physical equilibria are also possible, and thermodynamics is a powerful tool for the characterization of such equilibria. The existence of alternate crystal structures for a given compound can be successfully examined from an equilibrium viewpoint, and this approach is especially useful when establishing the relative stability of such polymorphic systems and their possible ability to interconvert.

Consider the situation presented by elemental sulfur, which can be obtained in either a rhombic or a monoclinic crystalline state. Each of these melts at a different temperature and is stable under certain well-defined environmental conditions. What are the conditions under which these two forms can equilibrate with liquid sulfur (either singly or together), and what are the conditions under which the two equilibrate in the absence of a liquid phase? These questions can be answered with the aid of chemical thermodynamics, the modern practice of which can be considered as beginning with publication of the seminal papers of J. Willard Gibbs [1].

Almost immediately after the law of conservation of mass was established, Gibbs showed that all cases of equilibria could be categorized

C:\stnweb\Queries\5.str





chain nodes :
7 8 10 20 21 22 23
ring nodes :
1 2 3 4 5 11 12 13 14 15 16 26 27 28 29 30 31
chain bonds :
2-7 4-8 5-10 10-14 11-20 20-21 21-22 22-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-12 11-16 12-13 13-14 14-15 15-16 26-27 26-31 27-28
28-29 29-30 30-31
exact/norm bonds :
2-3 2-7 3-4 4-8 11-20
exact bonds :
1-2 1-5 4-5 5-10 10-14 20-21 21-22 22-23
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16 26-27 26-31 27-28 28-29 29-30 30-31
isolated ring systems :
containing 1 : 11 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 10:CLASS 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS

Session text above this point is available in the transcript, available from the **Transcript Assistant** on the toolbar.

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:25:58 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:  27 APR 2004  HIGHEST RN 677274-15-6
DICTIONARY FILE UPDATES:  27 APR 2004  HIGHEST RN 677274-15-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1      STRUCTURE UPLOADED

=> d l2
L2 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l1
L1 HAS NO ANSWERS
L1              STR
```

O 27 S 28



Page 1-A



Page 1-B



Page 2-A



Page 2-B



Page 3-A



Page 3-B

Page 3-C

```
VAR G1=27/28
REP G19=(0-2) 18-17 18-19
REP G20=(1-2) 8-5 8-12
VPA 19-24/25/26 S
NODE ATTRIBUTES:
HCOUNT  IS M2     AT   8
HCOUNT  IS M2     AT  17
HCOUNT  IS M2     AT  18
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS C      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS C      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   8 16 17 18 19 27 28
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

```
RSPEC   9   5
NUMBER OF NODES IS  28

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 16:31:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED       6 ITERATIONS                                 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            6 TO      266
PROJECTED ANSWERS:               4 TO      200

L2            4 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:31:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    178 TO ITERATE

100.0% PROCESSED     178 ITERATIONS                             104 ANSWERS
SEARCH TIME: 00.00.01

L3          104 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   158.78     158.99

FILE 'HCAPLUS' ENTERED AT 16:31:37 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004  (20040427/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l3/thu
```

```
          897 L3
       588726 THU/RL
L4        631 L3/THU
                (L3 (L) THU/RL)

=> s l4 and diab?
       110839 DIAB?
L5        375 L4 AND DIAB?

=> s l5 and mellit?
        64075 MELLIT?
L6        305 L5 AND MELLIT?

=> s l6 and pd < may 2000
     20466207 PD < MAY 2000
                (PD<20000500)
L7         57 L6 AND PD < MAY 2000

=> s l7 and pd < may 1999
     19621652 PD < MAY 1999
                (PD<19990500)
L8         34 L7 AND PD < MAY 1999

=> d l8, ibib abs fhitstr, 1-34

L8   ANSWER 1 OF 34  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2000:362595 HCAPLUS
DOCUMENT NUMBER: 133:13403
TITLE: Adipocyte containing ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases
INVENTOR(S): Briggs, Michael R.; Auwerx, Johan; De Vos, Piet; Staels, Bart; Croston, Glenn E.; Miller, Stephen G.
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Inc., USA
SOURCE: U.S., 64 pp., Cont.-in-part of U.S. Ser. No. 558,588, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6068976	A	20000530	US 1996-618100	19960319
CA 2215387	AA	19960926	CA 1996-2215387	19960319 <--

PRIORITY APPLN. INFO.:

US 1995-408584	B2	19950320
US 1995-418096	B2	19950405
US 1995-510584	B2	19950802
US 1995-558588	B2	19951030
US 1995-7390P	P	19951121
US 1995-7721P	P	19951130
US 1995-8601P	P	19951214

AB This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathol. conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other

control regions of the ob gene. A PPARγ agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body wt. loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, **diabetes**, hypertension, cardiovascular diseases and infertility.

IT 122320-73-4, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(PPARγ agonist; adipocyte contg. ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:10630 HCAPLUS
DOCUMENT NUMBER: 132:44986
TITLE: Combinations of glitazones, biguanides, and optional sulfonylureas for treatment of **diabetes**
INVENTOR(S): Whitcomb, Randall Wayne
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 22 pp., Cont.-in-part of U.S. 5,859,037.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 6011049	A	20000104	US 1998-189132	19981109	<--
US 5859037	A	19990112	US 1997-970057	19971113	<--
CA 2345524	AA	20000518	CA 1999-2345524	19990811	
WO 2000027401	A1	20000518	WO 1999-US18140	19990811	
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9953473	A1	20000529	AU 1999-53473	19990811	
EP 1128834	A1	20010905	EP 1999-939130	19990811	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002529417	T2	20020910	JP 2000-580630	19990811	

PRIORITY APPLN. INFO.:

US 1997-38224P	P	19970219
US 1997-970057	A2	19971113
US 1998-189132	A	19981109
WO 1999-US18140	W	19990811

AB Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating **diabetes mellitus** and improving glycemic control.

IT **122320-73-4**, Rosiglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(combinations of glitazones, biguanides, and optional sulfonylureas for **diabetes** treatment)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:792188 HCAPLUS
DOCUMENT NUMBER: 132:18391
TITLE: Thiazolidinediones in the treatment of insulin resistance syndrome
AUTHOR(S): Cawthorne, M. A.
CORPORATE SOURCE: Clore Laboratory, University of Buckingham, Buckingham, MK18 1EG, UK
SOURCE: Progress in Obesity Research (**1999**), 8, 517-524
CODEN: POBREJ; ISSN: 0962-7936
PUBLISHER: John Libbey & Co. Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 14 refs. This article discusses the insulin sensitizing actions of thiazolidinediones, their mechanism of action, and preclin. and clin. effects in **diabetes** treatment.

IT **122320-73-4**, Rosiglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinediones in treatment of insulin resistance syndrome in humans)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:789202 HCAPLUS
DOCUMENT NUMBER: 132:117393
TITLE: Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism
AUTHOR(S): Furnsinn, C.; Brunmair, B.; Meyer, M.; Neschen, S.; Furtmuller, R.; Roden, M.; Kuhnle, H. F.; Nowotny, P.; Schneider, B.; Waldhausl, W.
CORPORATE SOURCE: Division of Endocrinology & Metabolism, Department of Medicine III, Vienna, A-1090, Austria
SOURCE: British Journal of Pharmacology (**1999**), 128(6), 1141-1148
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Stockton Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1 New thiazolidinediones BM13.1258 and BM15.2054 were studied with regard to their PPARγ-agonistic activities and to their acute and chronic effects on glucose metab. in soleus muscle strips from lean and genetically obese rats. 2 Both BM13.1258 and BM15.2054 revealed to be potent PPARγ-activators in transient transfection assays in vitro. 3 In insulin-resistant obese rats, but not in lean rats, 10 days of oral treatment with either compd. increased the stimulatory effect of insulin on muscle glycogen synthesis to a similar extent (insulin-induced

increment in μmol glucose incorporated into glycogen g-1 h-1: control, +1.19±0.28; BM13.1258, +2.50±0.20; BM15.2054, +2.55±0.46; P<0.05 vs control each). 4 In parallel to insulin sensitization, mean glucose oxidn. increased insulin independently in response to BM13.1258 (to 191 and 183% of control in the absence and presence of insulin, resp.; P<0.01 each), which was hardly seen in response to BM15.2054 (to 137 and 124% of control, resp.; ns). 5 Comparable effects on PPARγ activation and on amelioration of insulin resistance by BM13.1258 and BM15.2054 were therefore opposed by different effects on glucose oxidn. 6 In contrast to chronic oral treatment, acute exposure of muscles to BM13.1258 or BM15.2054 in vitro elicited a distinct catabolic response of glucose metab. in specimens from both lean and obese rats. 7 The results provide evidence that BM13.1258 and BM15.2054 can affect muscle glucose metab. via more than one mechanism of action. 8 Further efforts are required to clarify, to what extent other mechanisms besides insulin sensitization via the activation of PPARγ are involved in the antidiabetic actions of thiazolidinediones.

IT **122320-73-4**, Rosiglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinediones BM13.1258 and BM15.2054 chronic and acute effects on skeletal muscle glucose metab.)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:724649 HCAPLUS
DOCUMENT NUMBER: 132:202442
TITLE: Rosiglitazone: a new agent of the thiazolidinedione class for treatment of the type 2 **diabetic** patient
AUTHOR(S): Amato, Paul V.; Domenichini, David
CORPORATE SOURCE: Hartford Hospital, Hartford, CT, USA
SOURCE: Formulary (**1999**), 34(10), 825-826, 829-830, 832, 835
CODEN: FORMF9; ISSN: 1082-801X
PUBLISHER: Advanstar Communications, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 33 refs. Rosiglitazone is an orally active antidiabetic agent of the thiazolidinedione class. It was approved by the FDA in May, 1999, as monotherapy and in combination with metformin for the treatment of type 2 **diabetic** patients. As a potent agonist of peroxisome proliferator-activated receptor γ, rosiglitazone is theorized to improve glycemic control by improving insulin sensitivity in adipose tissue, skeletal muscle, and liver. Clin. trials of rosiglitazone as monotherapy and in combination with metformin, sulfonylureas, or insulin have shown clin. and significant effects on HbA1c and fasting blood glucose. The most common adverse effects have been respiratory tract infections, injury, and headache. Clin. data show no evidence of hepatotoxicity or elevations in liver enzymes. The usual starting dosage is 4 mg/day given once daily or in two divided doses; this dosage may be increased to 8 mg/day. Rosiglitazone appears to be an effective, safe, and competitively priced agent for the treatment of type 2 **diabetics**.

IT **122320-73-4**, Rosiglitazone
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(rosiglitazone: a new agent of the thiazolidinedione class for treatment of human type 2 **diabetes**)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:686705 HCAPLUS
DOCUMENT NUMBER: 131:281580
TITLE: Sulfonylurea-glitazone combinations for treatment of **diabetes**
INVENTOR(S): Whitcomb, Randall Wayne
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 15 pp., Cont.-in-part of U.S. 5,859,037.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5972973	A	19991026	US 1998-173911	19981016 <--
US 5859037	A	19990112	US 1997-970057	19971113 <--

PRIORITY APPLN. INFO.: US 1997-38224P P 19970219
US 1997-970057 A2 19971113

AB Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating **diabetes mellitus** and improving glycemic control.

IT 122320-73-4, Rosiglitazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological

study); USES (Uses)
(sulfonylurea-glitazone combinations for treatment of **diabetes**
)
RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:648143 HCAPLUS
DOCUMENT NUMBER: 131:237418
TITLE: Rosiglitazone: a new therapy for Type 2 **diabetes**
AUTHOR(S): Greene, Douglas A.
CORPORATE SOURCE: Michigan Diabetes Research and Training Center, University of Michigan Medical School, Ann Arbor, MI, 48109-0611, USA
SOURCE: Expert Opinion on Investigational Drugs (**1999**), 8(10), 1709-1719
CODEN: EOIDER; ISSN: 1354-3784
PUBLISHER: Ashley Publications
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 58 refs. Rosiglitazone (Avandia) is a new-generation thiazolidinedione used in the treatment of Type 2 **diabetes**. As with other thiazolidinediones, it binds to the γ-isoform of the peroxisome proliferator-activated receptor (PPAR), a nuclear hormone

receptor. Subsequent to PPAR-γ activation, rosiglitazone increases insulin suppression of hepatic glucose output and increases peripheral glucose uptake in the muscles, thereby improving the glycemic state of the individual. In rodent models of obesity and Type 2 **diabetes**, rosiglitazone has been shown to have pos. effects in the main target organs responsible for the condition: the liver, pancreas, skeletal muscle and adipose tissue. These studies also suggest that rosiglitazone may help in preserving renal and pancreatic function that deteriorates in chronic hyperinsulinemia. In clin. studies, rosiglitazone has been shown to be effective, safe and well tolerated, not only when used as monotherapy, but also when used in combination with sulfonylureas, metformin or insulin. Unlike troglitazone, rosiglitazone is not metabolized via cytochrome P 450 3A4 and is thus unlikely to be subject to clin. important drug interactions. In addn., no evidence of hepatotoxicity has been assocd. with rosiglitazone to date. Rosiglitazone should therefore be strongly considered as part of the overall management of Type 2 **diabetes**.

IT **122320-73-4**, Rosiglitazone
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(rosiglitazone therapy for type 2 **diabetes**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:642131 HCAPLUS
DOCUMENT NUMBER: 131:237808
TITLE: Rosiglitazone monotherapy improves glycemic control in patients with type 2 **diabetes**: a twelve-week, randomized, placebo-controlled study
AUTHOR(S): Patel, J.; Anderson, R. J.; Rappaport, E. B.
CORPORATE SOURCE: Clinical Research and Development, SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA
SOURCE: Diabetes, Obesity and Metabolism (**1999**), 1(3), 165-172
CODEN: DOMEF6; ISSN: 1462-8902
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study was designed to identify doses of rosiglitazone that would lower fasting plasma glucose (FPG) in patients with type 2 **diabetes**. In this 12-wk, double-blind, multicenter study, 380 patients with FPG values ≥7.8 mM (140 mg/dL) and ≤13.3 mM (240 mg/dL) were randomly assigned to receive treatment with placebo or rosiglitazone, at 0.05, 0.25, 1.0, or 2.0 mg twice daily (b.i.d.). The primary efficacy parameter was change in FPG from basal values after 12 wk of treatment. Secondary endpoints were changes in HbA1c, fructosamine, C peptide, insulin, lipid levels, and body wt. Safety monitoring included clin. lab. evaluations, electrocardiog., and echocardiog. Rosiglitazone at 1.0 and 2.0 mg b.i.d. produced significant decreases in FPG. Fructosamine also decreased in patients treated with these two dosages. Rosiglitazone at 2.0 mg b.i.d. reduced plasma insulin and free fatty acids compared with placebo. Total cholesterol and high- and low-d. lipoproteins increased in the rosiglitazone 2.0 mg b.i.d. group, but there was no significant change in the total cholesterol/high-d. lipoprotein ratio or triglyceride levels in any rosiglitazone treatment group. Clin. insignificant dose-dependent increases in body wt. were obsd. in the groups given rosiglitazone at 1.0 and 2.0 mg b.i.d. Thus, 12 wk of treatment with rosiglitazone at 2.0 mg b.i.d. decreases fasting plasma glucose, fructosamine, insulin, and free fatty acids in patients with type 2 **diabetes**.

IT **122320-73-4**, Rosiglitazone
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(rosiglitazone effect on glycemic control in humans with type 2 **diabetes**)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:425423 HCAPLUS
DOCUMENT NUMBER: 131:96689
TITLE: Rosiglitazone
AUTHOR(S): Balfour, Julia A. Barman; Plosker, Greg L.
CORPORATE SOURCE: Adis International Limited, Auckland, N. Z.
SOURCE: Drugs (**1999**), 57(6), 921-930
CODEN: DRUGAY; ISSN: 0012-6667
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 66 refs. Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key metabolic abnormality in most patients with type 2 (non-insulin-dependent) **diabetes mellitus**. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented **diabetic** nephropathy and pancreatic islet cell degeneration. In contrast to troglitazone, rosiglitazone does not induce cytochrome P 4503A4 metab. It does not interact significantly with nifedipine, oral contraceptives, metformin, digoxin, ranitidine or acarbose. In clin. trials in patients with type 2 **diabetes mellitus**, rosiglitazone at 2-12 mg/day (as a single daily dose or 2 divided daily doses) improved glycemic control, as shown by decreases in fasting plasma glucose and glycosylated Hb (HbA1c). Addn. of rosiglitazone at 2-8 mg/day to existing sulfonylurea, metformin or insulin therapy achieved further redns. in fasting plasma glucose and HbA1c. Oral combinations improved insulin

sensitivity and β-cell function according to a homeostasis model assessment. Consistent with its mechanism of action, rosiglitazone appears to be assocd. with a low risk of hypoglycemia (<2% of patients receiving monotherapy). There is no evidence to date that rosiglitazone shares the hepatotoxicity of troglitazone.

IT **122320-73-4**, Rosiglitazone
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(antidiabetic pharmacol. of rosiglitazone)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:325195 HCAPLUS
DOCUMENT NUMBER: 131:138770
TITLE: Rosiglitazone SmithKline Beecham plc
AUTHOR(S): Jones, Richard
CORPORATE SOURCE: Selly Oak Hospital Department of Clinical Biochemistry, Birmingham University NHS Trust, Birmingham, B29 6JD, UK
SOURCE: Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs (**1999**), 1(1), 65-75

CODEN: COODF2; ISSN: 1464-8466
PUBLISHER: Current Drugs Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with many refs. Rosiglitazone is under development by SmithKline Beecham (SB) as a potential treatment for non-insulin dependent **diabetes mellitus** (NIDDM). The compd. acts as an agonist at the peroxisome proliferator-activated receptor (PPAR)-γ receptor. Rosiglitazone, in common with the related but less potent troglitazone (from Sankyo), is a thiazolidinedione with insulin-sensitizing actions. Rosiglitazone works by preventing hyperglycemia without any propensity for hypoglycemia, reducing hyperinsulinemia, and improving insulin sensitivity, while at the same time lowering plasma levels of triglycerides and free fatty acids. A preclin. study showed that troglitazone is a more potent vasorelaxant than rosiglitazone, which is, in turn, more potent than any of its unconjugated metabolites. The data suggested that the vasorelaxant properties were related to calcium channel-blocking activity. The company submitted an NDA to the US FDA in Nov. 1998 for the treatment of type II **diabetes**, as both a monotherapy, and in combination with sulfonylureas, metformin and insulin. A six-month priority review was granted by the FDA in Jan. 1999, and according to Merrill Lynch, this indicates that the compd. could be launched by the third quarter of 1999. SB filed for European approval in Dec. 1998 for the treatment of type II **diabetes**. Merrill Lynch predicts an early 2000 approval. In Sept. 1998, Merrill Lynch forecast sales of $2 billion by 2003. Deutsche Morgan Grenfell forecast sales of $3 billion by the same year, while Lehman Brothers forecast sales of $500 million by 2002.

IT **122320-73-4**, Rosiglitazone
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(antidiabetic rosiglitazone for treatment of NIDDM)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 142 THERE ARE 142 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:272116 HCAPLUS
DOCUMENT NUMBER: 131:67946
TITLE: The RXR agonist LG100268 causes hepatomegaly, improves glycemic control, and decreases cardiovascular risk and cachexia in **diabetic** mice suffering from pancreatic beta-cell dysfunction
AUTHOR(S): Lenhard, J. M.; Lancaster, M. E.; Paulik, M. A.; Weiel, J. E.; Binz, J. G.; Sundseth, S. S.; Gaskill, B. A.; Lightfoot, R. M.; Brown, H. R.
CORPORATE SOURCE: Department Metabolic Disesases, Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA
SOURCE: Diabetologia (**1999**), 42(5), 545-554
CODEN: DBTGAJ; ISSN: 0012-186X
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Although retinoid X receptor (RXR) and peroxisome proliferator activated receptor-γ (PPARγ) agonists have antidiabetic effects in hyperinsulinemic animals, little information exists on their effects after pancreatic β-cell failure. The authors examd. if RXR and PPARγ agonists alter distinct metabolic pathways in animals suffering from impaired insulin secretion. Adverse side effects and antidiabetic responses were measured in db/db mice treated from 14-16 wk of age with the RXR agonist, LG100268, and/or the PPARγ agonists, BRL49653 or GW1929. In animals treated with LG100268 or BRL49653, blood glucose, glycoHb, and the cardiovascular risk factor, fibrinogen, decreased to the same extent. Both of these agonists were equally effective at increasing insulin accumulation in β cells, although neither agent had an effect on serum insulin concns. The RXR agonist was less effective than the PPARγ agonists at lowering serum triglycerides and non-esterified fatty acids and increasing interscapular brown fat and body wt. LG100268 increased serum alk. phosphatase and liver mass, hepatic fat accumulation, lauric acid hydroxylase activity, catalase-immunostaining, and peroxisomal no. more than the PPARγ agonists. Co-treatment with the RXR and PPARγ agonists reduced glucose, triglycerides, non-esterified fatty acids, and cholesterol more than either agent alone. These data suggest that RXR and PPARγ agonists decrease islet degeneration, cardiovascular risk and cachexia during later stages of **diabetes**. RXR agonists are less effective than PPARγ agonists at decreasing serum lipids and causing wt. gain. RXR agonists have a more pronounced effect on liver metab. (e.g. peroxisome accumulation and hepatomegaly) than PPARγ agonists.

IT **122320-73-4**, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological

study); USES (Uses)
(RXR and PPARγ agonist effect on liver, blood glucose and lipids, cardiovascular risk, and cachexia in **diabetes** with pancreatic β-cell dysfunction)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:167677 HCAPLUS
DOCUMENT NUMBER: 131:124868
TITLE: Systemic exposure to rosiglitazone is unaltered by food
AUTHOR(S): Freed, M. I.; Allen, A.; Jorkasky, D. K.; DiCicco, R. A.
CORPORATE SOURCE: SmithKline Beecham Clinical Pharmacology Unit, Presbyterian Medical Center of the University of Pennsylvania Health System, 51 North 39th Street, Philadelphia, PA, 19104, USA
SOURCE: European Journal of Clinical Pharmacology (**1999**), 55(1), 53-56
CODEN: EJCPAS; ISSN: 0031-6970
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: To evaluate the effect of food on the bioavailability and pharmacokinetics of the insulin sensitizer rosiglitazone. Methods: In a randomized, open-label, period-balanced, single-dose, crossover study, rosiglitazone 2 mg was administered to 12 healthy male volunteers either in the fasting state or following a std. high-fat breakfast. The primary end points of the study were AUC0-inf and Cmax. Results: Single oral doses of rosiglitazone were safe and well tolerated. Overall exposure to rosiglitazone was unaffected by food. The geometric mean ratio of AUC(0-inf) in the fed:fasted regimens was 0.94 (95% CI: 0.82, 1.06); t1/2was unaffected. Absorption of rosiglitazone in the fed state was more gradual and sustained than in the fasted state. Cmax was reduced by approx. 20% (point est. 0.80; 95% CI 0.65 to 0.97) and tmax was modestly delayed in the fed state. Conclusion: These data support dosing guidelines that will permit the administration of rosiglitazone without regard to meals for treatment of type 2 **diabetes mellitus**.

IT 122320-73-4, Rosiglitazone
RL: BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(bioavailability of antidiabetic rosiglitazone is unaltered by food intake in humans)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:81575 HCAPLUS
DOCUMENT NUMBER: 130:134189
TITLE: Treatment of **diabetes** with a thiazolidinedione, an insulin secretagogue, and an α-glucosidase inhibitor
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9903478	A1	19990128	WO 1998-GB2112	19980716	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9884490	A1	19990210	AU 1998-84490	19980716	<--
EP 1001784	A1	20000524	EP 1998-935129	19980716	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810292	A	20000919	BR 1998-10292	19980716	
JP 2001510160	T2	20010731	JP 2000-502777	19980716	
ZA 9806364	A	20000117	ZA 1998-6364	19980717	<--
BG 104062	A	20001130	BG 2000-104062	20000106	
NO 2000000230	A	20000117	NO 2000-230	20000117	<--
US 2002052324	A1	20020502	US 2001-989572	20011120	
US 2003092750	A1	20030515	US 2002-322982	20021218	

PRIORITY APPLN. INFO.:		
GB 1997-15298	A	19970718
WO 1998-GB2112	W	19980716
US 1999-445908	A1	19991215
US 2001-989572	B1	20011120

AB A method and compn. are disclosed for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal. The method comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer, an insulin secretagogue and an α-glucosidase inhibitor antihyperglycemic agent to a mammal in need thereof.

IT **122320-73-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinedione, insulin secretagogue, and α-glucosidase inhibitor for **diabetes** treatment)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:81574 HCAPLUS
DOCUMENT NUMBER: 130:134188
TITLE: Treatment of **diabetes** with a thiazolidinedione, an insulin secretagogue, and a biguanide
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903477	A1	19990128	WO 1998-GB2110	19980716 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9884488	A1	19990210	AU 1998-84488	19980716 <--

EP 1001783	A1	20000524	EP 1998-935127	19980716	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810445	A	20000905	BR 1998-10445	19980716	
NZ 501164	A	20010629	NZ 1998-501164	19980716	
JP 2001510159	T2	20010731	JP 2000-502776	19980716	
NZ 511608	A	20021220	NZ 1998-511608	19980716	
ZA 9806363	A	20000117	ZA 1998-6363	19980717	<--
TW 505516	B	20021011	TW 1998-87111770	19980717	
NO 2000000228	A	20000117	NO 2000-228	20000117	<--
BG 104135	A	20001031	BG 2000-104135	20000207	
US 2002016287	A1	20020207	US 2001-939470	20010824	

PRIORITY APPLN. INFO.:

GB 1997-15295	A	19970718
NZ 1998-501164	A1	19980716
WO 1998-GB2110	W	19980716
US 1999-446039	A1	19991215

AB A method and compn. are disclosed for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal. The method comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer, an insulin secretagogue and a biguanide antihyperglycemic agent to a mammal in need thereof.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thiazolidinedione, insulin secretagogue, and biguanide for **diabetes** treatment)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:81573 HCAPLUS
DOCUMENT NUMBER: 130:134187
TITLE: Treatment of **diabetes** with insulin sensitizer thiazolidinedione and insulin secretagogue sulfonylurea
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9903476	A1	19990128	WO 1998-GB2109	19980716	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9884487	A1	19990210	AU 1998-84487	19980716	<--
AU 743269	B2	20020124			
EP 998291	A1	20000510	EP 1998-935126	19980716	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810904	A	20000926	BR 1998-10904	19980716	
JP 2001510158	T2	20010731	JP 2000-502775	19980716	
NZ 501256	A	20020927	NZ 1998-501256	19980716	
NZ 515555	A	20020927	NZ 1998-515555	19980716	
ZA 9806365	A	20000117	ZA 1998-6365	19980717	<--
NO 2000000229	A	20000117	NO 2000-229	20000117	<--
BG 104139	A	20001130	BG 2000-104139	20000208	
US 2002045649	A1	20020418	US 2001-975883	20011012	
US 2003109561	A1	20030612	US 2003-346947	20030117	

PRIORITY APPLN. INFO.:

GB 1997-15306	A	19970718
NZ 1998-501256	A1	19980716
WO 1998-GB2109	W	19980716
US 1999-445907	A1	19991215
US 2001-975883	B1	20011012

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amt. of an insulin sensitizer and a sub-maximal amt. of an insulin secretagogue, to a mammal in need thereof; and a pharmaceutical compn. for

use in such method are disclosed. The insulin secretagogue is esp. sulfonylurea. The insulin sensitizer is esp. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (I). Tablet formulations contg. I maleate are given.

IT 122320-73-4

RL: **THU (Therapeutic use)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)

(as insulin sensitizer; treatment of **diabetes** with insulin sensitizer thiazolidinedione and insulin secretagogue sulfonylurea)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:45152 HCAPLUS
DOCUMENT NUMBER: 130:90519
TITLE: Sulfonylurea-glitazone combinations for **diabetes**
INVENTOR(S): Whitcomb, Randall Wayne
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 31 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5859037	A	19990112	US 1997-970057	19971113 <--
US 5972973	A	19991026	US 1998-173911	19981016 <--
US 6011049	A	20000104	US 1998-189132	19981109 <--

PRIORITY APPLN. INFO.: US 1997-38224P P 19970219
US 1997-970057 A2 19971113

AB Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating **diabetes mellitus** and improving glycemic control.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sulfonylurea-glitazone combinations for **diabetes**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9712 HCAPLUS
DOCUMENT NUMBER: 130:61091
TITLE: Treatment of **diabetes** with thiazolidinedione and

sulfonylurea
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9857649	A1	19981223	WO 1998-EP3688	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9885392	A1	19990104	AU 1998-85392	19980615	<--
EP 999845	A1	20000517	EP 1998-936363	19980615	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810142	A	20000808	BR 1998-10142	19980615	
JP 2001523270	T2	20011120	JP 1999-503754	19980615	
NZ 501163	A	20020201	NZ 1998-501163	19980615	
ZA 9805236	A	20000217	ZA 1998-5236	19980617	<--
NO 9906264	A	20000217	NO 1999-6264	19991217	<--
BG 104058	A	20001031	BG 2000-104058	20000106	
US 2001049380	A1	20011206	US 2001-848511	20010502	
US 2002147226	A1	20021010	US 2002-103326	20020321	

PRIORITY APPLN. INFO.:

GB 1997-12854	A	19970618
GB 1998-6710	A	19980327
WO 1998-EP3688	W	19980615
US 1999-445859	B1	19991215
US 2001-848511	B1	20010502

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer and an insulin secretagogue, to a mammal in need thereof.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes** with thiazolidinedione and sulfonylurea)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9699 HCAPLUS
DOCUMENT NUMBER: 130:61090
TITLE: Treatment of **diabetes** with rosiglitazone and insulin
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9857636	A1	19981223	WO 1998-EP3692	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9882163	A1	19990104	AU 1998-82163	19980615	<--
EP 999837	A1	20000517	EP 1998-932169	19980615	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810444	A	20000905	BR 1998-10444	19980615	
JP 2002504138	T2	20020205	JP 1999-503757	19980615	
CN 1133431	B	20040107	CN 1998-806223	19980615	
NZ 518076	A	20040227	NZ 1998-518076	19980615	
ZA 9805237	A	20000217	ZA 1998-5237	19980617	<--
NO 9906265	A	19991217	NO 1999-6265	19991217	<--
MX 9912065	A	20000831	MX 1999-12065	19991217	
BG 104059	A	20001031	BG 2000-104059	20000106	
US 2002028768	A1	20020307	US 2001-928326	20010813	

PRIORITY APPLN. INFO.:	GB 1997-12866	A	19970618
	NZ 1998-501259	A1	19980615
	WO 1998-EP3692	W	19980615
	US 1999-445858	B1	19991215

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective nontoxic and pharmaceutically acceptable amt. of insulin sensitizer rosiglitazone and insulin to a mammal in need thereof.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes mellitus** with rosiglitazone and insulin)

RN 155141-29-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9698 HCAPLUS
DOCUMENT NUMBER: 130:76189
TITLE: Treatment of **diabetes** with thiazolidinedione and alpha-glucosidase inhibitor
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9857635	A1	19981223	WO 1998-EP3691	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9887999	A1	19990104	AU 1998-87999	19980615	<--
EP 975343	A1	20000202	EP 1998-939513	19980615	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810186	A	20000808	BR 1998-10186	19980615	
JP 2001523271	T2	20011120	JP 1999-503756	19980615	
ZA 9805235	A	20000217	ZA 1998-5235	19980617	<--
NZ 501345	A	20011026	NZ 1998-501345	19980715	
NO 9906270	A	19991217	NO 1999-6270	19991217	<--
MX 9912098	A	20000831	MX 1999-12098	19991217	
US 2001034356	A1	20011025	US 2001-863136	20010523	
US 2002123514	A1	20020905	US 2002-91008	20020305	
US 2003073645	A1	20030417	US 2002-290132	20021107	

PRIORITY APPLN. INFO.:

GB 1997-12865	A	19970618
GB 1998-6708	A	19980327
WO 1998-EP3691	W	19980615
US 1999-445951	B1	19991215
US 2001-863136	B1	20010523
US 2002-91008	B1	20020305

GI



I

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amt. of an insulin sensitizer (I) and an α-glucosidase inhibitor antihyperglycemic agent. The effects of α-glucosidase inhibitor acarbose on the pharmacokinetics of I in healthy humans are described along with pharmaceutical formulations (concns. and tablets) contg. I.

IT **155141-29-0**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes mellitus** and conditions assocd. with **diabetes** with thiazolidinedione deriv. and α-glucosidase inhibitors)

RN 155141-29-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met

hyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9697 HCAPLUS
DOCUMENT NUMBER: 130:61089
TITLE: Treatment of **diabetes** with thiazolidinedione and metformin
INVENTOR(S): Smith, Stephen Alistair

PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9857634	A1	19981223	WO 1998-EP3690	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9885393	A1	19990104	AU 1998-85393	19980615	<--
EP 996444	A1	20000503	EP 1998-936364	19980615	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810172	A	20000808	BR 1998-10172	19980615	
JP 2002504137	T2	20020205	JP 1999-503755	19980615	
NZ 501260	A	20020927	NZ 1998-501260	19980615	
CN 1114404	B	20030716	CN 1998-806224	19980615	
NZ 515554	A	20030926	NZ 1998-515554	19980615	
ZA 9805238	A	20000217	ZA 1998-5238	19980617	<--
NO 9906266	A	19991217	NO 1999-6266	19991217	<--
MX 9912078	A	20000831	MX 1999-12078	19991217	
BG 104060	A	20001031	BG 2000-104060	20000106	
US 2002004515	A1	20020110	US 2001-925394	20010809	
US 2002137772	A1	20020926	US 2002-99161	20020313	
CN 1429551	A	20030716	CN 2002-156128	20021206	
US 2003109553	A1	20030612	US 2003-340426	20030110	

PRIORITY APPLN. INFO.:

GB 1997-12857	A	19970618
GB 1998-6706	A	19980327
NZ 1998-501260	A1	19980615
WO 1998-EP3690	W	19980615
US 1999-446030	B1	19991215
US 2001-925394	B1	20010809
US 2002-99161	B1	20020313

AB A method for the treatment and/or prophylaxis of **diabetes mellitus**, conditions assocd. with **diabetes mellitus**, and certain complications thereof, in a mammal which method comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer rosiglitazone (I) and a biguanide antihyperglycemic agent such as metformin. Pharmacokinetics of I and metformin administered alone or in combination are described. Formulations for prepg. tablets contg. I is presented.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes** with thiazolidinedione insulin sensitizer and metformin)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:764284 HCAPLUS
DOCUMENT NUMBER: 130:10664
TITLE: Use of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational **diabetes**

INVENTOR(S): Antonucci, Tammy; Lockwood, Dean; Norris, Rebecca
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9851305	A1	19981119	WO 1998-US10113	19980514	<--
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
ZA 9804084	A	19981120	ZA 1998-4084	19980514	<--
AU 9874949	A1	19981208	AU 1998-74949	19980514	<--
AU 731690	B2	20010405			
EP 981346	A1	20000301	EP 1998-922391	19980514	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 9809120	A	20000801	BR 1998-9120	19980514	
JP 2001525827	T2	20011211	JP 1998-549654	19980514	
AU 9952576	A1	19991202	AU 1999-52576	19991001	<--
AU 749416	B2	20020627			
NO 9905549	A	19991112	NO 1999-5549	19991112	<--

PRIORITY APPLN. INFO.:		
US 1997-856987	A	19970515
AU 1997-17709	A3	19970403
WO 1998-US10113	W	19980514

AB Novel methods of using thiazolidinone derivs. and related antihyperglycemic agents to treat populations at risk for developing noninsulin-dependent **diabetes mellitus** (NIDDM) and complications arising therefrom are disclosed. In one embodiment, the compds. of the invention are used to treat polycystic ovary syndrome to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**. In another embodiment, the compds. of the invention are used to treat gestational **diabetes** to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**.

IT **122320-73-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(ste ns treatment of polycystic ovary syndrome and gestational **diabetes** and prevention of NIDDM development by (methyl)pyridyl)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:672463 HCAPLUS
DOCUMENT NUMBER: 129:270626
TITLE: Methods and compositions for treating and/or preventing non-insulin dependent **diabetes mellitus** (NIDDM) using specific retinoid compounds
INVENTOR(S): Pfahl, Magnus; Lernhardt, Waldemar; Fanjol, Andrea
PATENT ASSIGNEE(S): Centre International de Recherches Dermatologiques Galderma, Fr.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842340	A1	19981001	WO 1998-US5591	19980324 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,

GA, GN, ML, MR, NE, SN, TD, TG

AU 9865763	A1	19981020	AU 1998-65763	19980324 <--
EP 1019049	A1	20000719	EP 1998-911919	19980324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9808054	A	20001107	BR 1998-8054	19980324
NZ 337927	A	20001124	NZ 1998-337927	19980324
JP 2001521551	T2	20011106	JP 1998-545851	19980324
NO 9904612	A	19991124	NO 1999-4612	19990902 <--
MX 9908765	A	20000731	MX 1999-8765	19990924

PRIORITY APPLN. INFO.:

US 1997-35604P	P	19970324
WO 1998-US5591	W	19980324

AB Methods are provided for treating and/or preventing non-insulin dependent **diabetes mellitus** (NIDDM) in subjects having or at substantial risk of developing NIDDM, using specific retinoid compds. that are structurally related to 9-cis retinoid acid which induce the differentiation of preadipocytes into adipocytes. These compds. may be administered alone or in combination with other anti-**diabetogenic** agents such as thiazolidinediones.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(retinoid compds. with other agents for treating and/or preventing non-insulin dependent **diabetes mellitus**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:603199 HCAPLUS
DOCUMENT NUMBER: 129:198010
TITLE: Sulfonylurea-glitazone synergistic combinations for **diabetes**
INVENTOR(S): Whitcomb, Randall W.
PATENT ASSIGNEE(S): Warner Lambert Co., USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9836755	A1	19980827	WO 1997-US21996	19971201	<--
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9855908	A1	19980909	AU 1998-55908	19971201	<--
AU 741215	B2	20011129			
EP 957923	A1	19991124	EP 1997-952250	19971201	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
EE 9900345	A	20000215	EE 1999-345	19971201	<--
CN 1244801	A	20000216	CN 1997-181434	19971201	<--
BR 9714505	A	20000321	BR 1997-14505	19971201	<--
JP 2001512478	T2	20010821	JP 1998-536611	19971201	
NZ 336002	A	20020328	NZ 1997-336002	19971201	
ZA 9801343	A	19981116	ZA 1998-1343	19980218	<--
NO 9903982	A	19990818	NO 1999-3982	19990818	<--

PRIORITY APPLN. INFO.: US 1997-38224P P 19970219
WO 1997-US21996 W 19971201

OTHER SOURCE(S): MARPAT 129:198010

AB Combinations of a sulfonylurea antidiabetic agent (e.g. glyburide) and a glitazone antidiabetic agent (e.g. troglitazone) are useful for treating **diabetes mellitus** and improving glycemic control.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sulfonylurea-glitazone synergistic combinations for **diabetes**)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:518786 HCAPLUS
DOCUMENT NUMBER: 129:229515
TITLE: The short- and long-term effects of tumor necrosis factor-α and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)γ2 gene expression and other adipocyte genes
AUTHOR(S): Edelstein Rosenbaum, Susan; Greenberg, Andrew S.
CORPORATE SOURCE: The USDA Human Nutrition Research Center on Aging at Tufts, Tupper Medical Research Institute New England Medical Center Boston, University and Division of Endocrinology, Boston, MA, 02111, USA
SOURCE: Molecular Endocrinology (**1998**), 12(8), 1150-1160
CODEN: MOENEN; ISSN: 0888-8809
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Expression of tumor necrosis factor-α (TNFα) in adipocytes has been reported to correlate with insulin resistance assocd. with obesity. The thiazolidinediones such as BRL 49653 have been reported to improve insulin sensitivity in obese animals and humans. Although its exact mechanism of action is not known, BRL 49653 has been shown to antagonize some of the inhibitory actions of TNFα. BRL 49653 binds and activates the peroxisome proliferator-activated receptor (PPARγ2), an important nuclear transcription factor in adipocyte differentiation;

however, its regulation of PPARγ2 in differentiated adipocytes is unknown. Here, the authors find that BRL 49653 blocked the ability of TNFα to down-regulate the expression and transcription of several adipocyte genes, but BRL 49653 did not prevent TNFα from down-regulating PPARγ2. Moreover, BRL 49653 alone initially decreased the expression of PPARγ2 mRNA and protein greatly. After 24 h of treatment in 3T3-L1 adipocytes, BRL 49653 down-regulated PPARγ2 by greater than 90% and potentiated the decrease of PPARγ2 mRNA by TNFα at this time. These unexpected results prompted the authors to repeat the expts. for a longer time to det. whether BRL 49653 would continue to down-regulate PPARγ2. With prolonged BRL 49653 treatment, PPARγ2 mRNA expression was not decreased as greatly, and the protein levels were decreased 20-30% below control at 72 h compared to 90% at 24 h. Although BRL 49653 continued to prevent the inhibitory effects of TNFα on perilipin and aP2 mRNA, by 72 h, BRL 49653 was not as potent an inhibitor of TNFα's down-regulation of perilipin protein. Since PPARγ2 protein was more abundant at this time, these results suggest that the level of PPARγ2 protein is not the sole factor that regulates the transcriptional control by BRL 49653.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(short- and long-term effects of tumor necrosis factor-α and BRL 49653 on peroxisome proliferator-activated receptor γ2 gene expression and other adipocyte genes)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:388148 HCAPLUS
DOCUMENT NUMBER: 129:117800
TITLE: Specific activation of the nuclear receptors PPARγ and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608
AUTHOR(S): Wiesenberg, Irmgard; Chiesi, Michele; Missbach, Martin; Spanka, Carsten; Pignat, Werner; Carlberg, Carsten
CORPORATE SOURCE: Pharma Research, Novartis Pharma AG, Basel, CH-4002, Switz.
SOURCE: Molecular Pharmacology (**1998**), 53(6), 1131-1138
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The thiazolidinedione BRL 49653 and the thiazolidinedione deriv. CGP 52608 are lead compds. of two pharmacol. different classes of compds. BRL 49653 is a high affinity ligand of peroxisome proliferator-activated receptor γ (PPARγ) and a prototype of novel antidiabetic agents, whereas CGP 52608 activates retinoic acid receptor-related orphan receptor α (RORA) and exhibits potent antiarthritic activity. Both receptors belong to the superfamily of nuclear receptors and are structurally related transcription factors. We tested BRL 49653 and CGP 52608 for receptor specificity on PPARγ, RORA, and retinoic acid receptor α, a closely related receptor to RORA, and compared their pharmacol. properties in in vitro and in vivo models in which these compds. have shown typical effects. BRL 49653 specifically induced PPARγ-mediated gene activation, whereas CGP 52608 specifically activated RORA in transiently transfected cells. Both compds. were active in nanomolar concns. Leptin prodn. in differentiated adipocytes was inhibited by nanomolar concns. of BRL 49653 but not by CGP 52608. BRL 49653 antagonized wt. loss, elevated blood glucose levels, and elevated plasma triglyceride levels in an in vivo model of glucocorticoid-induced insulin resistance in rats, whereas CGP 52608 exhibited steroid-like effects on triglyceride levels and body wt. in this model. In contrast, potent antiarthritic activity in rat adjuvant arthritis was shown for CGP 52608, whereas BRL 49653 was nearly inactive. Our results support the concept that transcriptional control mechanisms via the nuclear receptors PPARγ and RORA are responsible at least in part for the different pharmacol. properties of BRL 49653 and CGP 52608. Both compds. are prototypes of interesting novel therapeutic agents for the treatment of non-insulin-dependent **diabetes mellitus** and rheumatoid arthritis.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(specific activation of nuclear receptors PPARγ and RORA by

antidiabetic thiazolidinedione BRL 49653 and antiarthritic thiazolidinedione deriv. CGP 52608)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:41808 HCAPLUS

DOCUMENT NUMBER: 128:123811

TITLE: Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin-resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**

INVENTOR(S): Olefsky, Jerrold M.

PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan

SOURCE: U.S., 16 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5708012 A 19980113 US 1995-431266 19950428 <--
PRIORITY APPLN. INFO.: US 1995-431266 19950428
OTHER SOURCE(S): MARPAT 128:123811

AB Methods are disclosed for using thiazolidinone derivs. and related antihyperglycemic agents to treat populations exhibiting insulin-resistant non-impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent **diabetes mellitus** and complications arising therefrom. In an outpatient trial with nondiabetic, obese patients, some of whom had impaired glucose tolerance, (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) normalized glucose tolerance and markedly improved insulin resistance and hyperinsulinemia.

IT **122320-73-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinedione derivs. and related antihyperglycemic agents in treatment of insulin-resistant subjects with normal glucose tolerance to prevent or delay onset of noninsulin-dependent **diabetes mellitus**)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:808815 HCAPLUS
DOCUMENT NUMBER: 128:136363
TITLE: Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
AUTHOR(S): Adams, Maria; Montague, Carl T.; Prins, Johannes B.; Holder, Julie C.; Smith, Stephen A.; Sanders, Louise; Digby, Jan E.; Sewter, Ciaran P.; Lazar, Mitchell A.; Chatterjee, V. Krishna K.; O'rahilly, Stephen
CORPORATE SOURCE: Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, CB2 2QQ, UK
SOURCE: Journal of Clinical Investigation (**1997**), 100(12), 3149-3153
CODEN: JCINAO; ISSN: 0021-9738
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Activation of peroxisome proliferator-activated receptor (PPAR) γ, a nuclear receptor highly expressed in adipocytes, induces the differentiation of murine preadipocyte cell lines. Recently, thiazolidinediones (TZDs), a novel class of insulin-sensitizing compds. effective in the treatment of non-insulin-dependent **diabetes mellitus** (NIDDM) have been shown to bind to PPARγ with high affinity. We have examd. the effects of these compds. on the differentiation of human preadipocytes derived from s.c. and omental (Om) fat. Assessed by lipid accumulation, glycerol 3-phosphate dehydrogenase activity, and mRNA levels, subcultured preadipocytes isolated from either s.c. or Om depots did not differentiate in defined serum-free medium. Addn. of TZDs (BRL49653 or troglitazone) or 15-deoxy Δ12,14 prostaglandin J2 (a natural PPARγ ligand) enhanced markedly the differentiation of preadipocytes from s.c. sites, assessed by all three criteria. The rank order of potency of these agents in inducing differentiation matched their ability to activate transcription via human PPARγ. In contrast, preadipocytes from Om sites in the same individuals were refractory to TZDs, although PPARγ was expressed at similar levels in both depots. The mechanism of this depot-specific TZD response is unknown. However, given the assocn. between Om adiposity and NIDDM, the site-specific responsiveness of human preadipocytes to TZDs may be involved in the beneficial effects of these compds. on in vivo insulin sensitivity.

IT **122320-73-4**, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(depot-specific effects of thiazolidinediones on differentiation of human preadipocytes as activators of PPARγ receptor and insulin sensitizers)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:329275 HCAPLUS
DOCUMENT NUMBER: 126:308792
TITLE: Treating NIDDM with RXR agonists
INVENTOR(S): Heyman, Richard A.; Cesario, Rosemary; Mukherjee, Ranjan
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710819	A1	19970327	WO 1996-US14904	19960917 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
CA 2232288	AA	19970327	CA 1996-2232288	19960917 <--
AU 9670742	A1	19970409	AU 1996-70742	19960917 <--

AU 725998	B2	20001026			
EP 859608	A1	19980826	EP 1996-931613	19960917	<--
EP 859608	B1	20040211			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
BR 9610624	A	19990316	BR 1996-10624	19960917	<--
JP 11511472	T2	19991005	JP 1996-512842	19960917	<--
US 6028052	A	20000222	US 1996-710309	19960917	<--
RU 2191007	C2	20021020	RU 1998-107335	19960917	
EP 1336600	A2	20030820	EP 2003-7532	19960917	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
AT 259227	E	20040215	AT 1996-931613	19960917	
US 5972881	A	19991026	US 1997-979725	19971126	<--
NO 9801192	A	19980518	NO 1998-1192	19980317	<--
US 6228862	B1	20010508	US 1999-309370	19990511	
US 6545049	B1	20030408	US 1999-388888	19990902	
US 6316404	B1	20011113	US 2000-745681	20001222	
AU 767255	B2	20031106	AU 2001-18372	20010209	
US 2002193291	A1	20021219	US 2001-850879	20010507	
US 6521633	B2	20030218			
US 2004019072	A1	20040129	US 2003-360580	20030205	

PRIORITY APPLN. INFO.:	US 1995-3869P	P	19950918
	US 1995-4897P	P	19951006
	US 1996-9884P	P	19960110
	US 1996-18318P	P	19960524
	US 1996-21839P	P	19960710
	AU 1996-73624	A3	19960917
	EP 1996-935837	A3	19960917
	US 1996-710309	B3	19960917
	US 1996-710427	B3	19960917
	WO 1996-US14904	W	19960917
	US 1997-979725	A1	19971126
	US 1999-309370	A3	19990511
	US 1999-388888	A3	19990902

AB This invention relates to methods and compns. for the treatment of non-insulin-dependent **diabetes mellitus** using an RXR agonist alone or in combination with a PPARγ agonist such as thiazolidine dione compd. Example RXR agonists are LGD 1069, ALRT 1957 and LG 100268.

IT **122320-73-4**, BRL 49653
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(noninsulin dependent **diabetes** treatment with RXR agonists)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:231131 HCAPLUS
DOCUMENT NUMBER: 126:207528
TITLE: A thiazolidione derivative for reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent **diabetes mellitus**
INVENTOR(S): Whitcomb, Randall W.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Whitcomb, Randall W.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705875	A2	19970220	WO 1996-US12430	19960729 <--
WO 9705875	A3	19970327		
W: AU, BG, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2221241	AA	19970220	CA 1996-2221241	19960729 <--
AU 9666411	A1	19970305	AU 1996-66411	19960729 <--
AU 724989	B2	20001005		
EP 851757	A2	19980708	EP 1996-926171	19960729 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				

CN 1192683	A	19980909	CN 1996-196191		19960729	<--
JP 11510508	T2	19990914	JP 1997-508479		19960729	<--
NZ 313874	A	20000929	NZ 1996-313874		19960729	
NO 9800556	A	19980209	NO 1998-556		19980209	<--
PRIORITY APPLN. INFO.:			US 1995-2098P	P	19950810	
			WO 1996-US12430	W	19960729	

OTHER SOURCE(S): MARPAT 126:207528

AB This invention provides a method of reducing the amt. of exogenous insulin administered to a patient having noninsulin-dependent **diabetes mellitus** by administering to a patient a therapeutically effective amt. of a thiazolidione deriv. and/or a related compd. Seventeen patients with noninsulin-dependent **diabetes mellitus** that were still on insulin were treated with thiazolidinedione deriv. (400 mg/day) for 8 wk. Ten patients have had a mean decrease of 45% (39 units) in their daily dose of insulin and appear to be continuing to reduce their insulin requirements. At the same time, their glycemic control was improving with a mean decrease of 15% (36 mg/dL) in blood glucose. A total of 7 patients have had their insulin discontinued after 8 wk.

IT **122320-73-4**, BRL 49653

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thiazolidione deriv. and/or related compds. for reducing amt. of exogenous insulin in humans with noninsulin-dependent **diabetes mellitus**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:221849 HCAPLUS
DOCUMENT NUMBER: 126:301937
TITLE: Sensitization of **diabetic** and obese mice to insulin by retinoid X receptor agonists
AUTHOR(S): Mukherjee, Ranjan; Davies, Peter J. A.; Crombie, Diane L.; Bischoff, Eric D.; Cesario, Rosemary M.; Jow, Lily; Hamann, Lawrence G.; Boehm, Marcus F.; Mondon, Carl E.; Nadzan, Alex M.; Paterniti, James R., Jr.; Heyman, Richard A.
CORPORATE SOURCE: Dep. Retinoid Res., San Diego, CA, 92121, USA
SOURCE: Nature (London) (**1997**), 386(6623), 407-410
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Macmillan Magazines
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Retinoic acid receptors (RAR), thyroid hormone receptors (TR), peroxisome proliferator activated receptors (PPARs) and the orphan receptor, LXR, bind preferentially to DNA as heterodimers with a common partner, retinoid X receptor (RXR), to regulate transcription. The authors investigated whether RXR-selective agonists replicate the activity of ligands for several of these receptors. It is demonstrated here that RXR-selective ligands (referred to as rexinoids) function as RXR heterodimer-selective agonists, activating RXR: PPARγ and RXR:LXR dimers but not RXR:RAR or RXR:TR heterodimers. Because PPARγ is a target for antidiabetic agents, it was investigated whether RXR ligands could alter insulin and glucose signaling. In mouse models of non-insulin-dependent **diabetes mellitus** (NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycemia, hypertriglyceridemia and hyperinsulinemia. This antidiabetic activity can be further enhanced by combination treatment with PPARγ agonists, such as thiazolidinediones. Apparently, the RXR:PPARγ heterodimer is a single-function complex serving as a mol. target for treatment of insulin resistance. Activation of the RXR:PPARγ dimer with rexinoids may provide a new and effective treatment for NIDDM.

IT **122320-73-4**, BRL 49653
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(sensitization of **diabetic** and obese mice to insulin by retinoid X receptor agonists)
RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1997:7888 HCAPLUS
DOCUMENT NUMBER: 126:99145
TITLE: The thiazolidinedione insulin sensitizer, BRL 49653, increases the expression of PPAR-γ and aP2 in adipose tissue of high-fat-fed rats
AUTHOR(S): Pearson, S. L.; Cawthorne, M. A.; Clapham, J. C.; Dunmore, S. J.; Holmes, S. D.; Moore, G. B. T.; Smith, S. A.; Tadayyon, M.
CORPORATE SOURCE: Clore Lab., Univ. Buckingham, Buckinghamshire, MK18 1EG, UK
SOURCE: Biochemical and Biophysical Research Communications (**1996**), 229(3), 752-757
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of the thiazolidinedione insulin sensitizer BRL 49653 on plasma leptin concns. and on epididymal fat OB, PPAR-γ and aP2 mRNA expression were examd. in high-fat-fed and high-carbohydrate-fed adult Wistar rats. Diets were given for 4 wk, with BRL 49653 (10 μmol/kg/day) administered by oral gavage for the last 4 days. Treatment with BRL 49653 reduced plasma leptin concns. in high-fat-fed rats from 2.34±0.19 to 1.42±0.09 ng/mL. Plasma leptin was unaffected by BRL 49653 in the high-carbohydrate-fed rats. There was no difference in OB mRNA expression between high-fat-fed and

high-carbohydrate-fed rats, with or without treatment. PPAR-γ and aP2 mRNA expression were significantly increased in the high-fat-fed rats treated with BRL 49653 (and resp.), but not in carbohydrate-fed rats.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinedione insulin sensitizer, BRL 49653, increases expression of PPAR-γ and aP2 in adipose tissue of high-fat-fed rats)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:713048 HCAPLUS
DOCUMENT NUMBER: 125:319877
TITLE: Adipocyte containing ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases
INVENTOR(S): Briggs, Michael R.; Auwerx, Johan; De Vos, Piet; Staels, Bart; Croston, Glenn E.; Miller, Stephen G.
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Incorporated, USA; Institut Pasteur De Lille
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629405	A2	19960926	WO 1996-US3808	19960319 <--
WO 9629405	A3	19961128		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML

CA 2215387	AA	19960926	CA 1996-2215387	19960319 <--
AU 9655248	A1	19961008	AU 1996-55248	19960319 <--
EP 815230	A2	19980107	EP 1996-912428	19960319 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.:

US 1995-408584	A	19950320
US 1995-418096	A	19950405
US 1995-510584	A	19950802
US 1995-558588	A	19951030
US 1995-7390P	P	19951121
US 1995-7721P	P	19951130
US 1995-8601P	P	19951214
WO 1996-US3808	W	19960319

AB This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathol. conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPARγ agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body wt. loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, **diabetes**, hypertension, cardiovascular diseases and infertility.

IT **122320-73-4**, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(PPARγ agonist; adipocyte contg. ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1996:71475 HCAPLUS
DOCUMENT NUMBER: 124:106679
TITLE: Thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**
INVENTOR(S): Olefsky, Jerrold; Antonucci, Tammy; Lockwood, Dean; Norris, Rebecca
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 122,251, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5478852	A	19951226	US 1994-293899	19940823 <--
US 5478852	C1	20010313		
WO 9507697	A2	19950323	WO 1994-US10187	19940909 <--
WO 9507697	A3	19950511		
W: AU, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 9507694	A1	19950323	WO 1994-US10389	19940914 <--
W: AU, CA, CN, CZ, FI, HU, JP, KR, MW, NO, NZ, RU				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9478351	A1	19950403	AU 1994-78351	19940914	<--
AU 679572	B2	19970703			
EP 719140	A1	19960703	EP 1994-929204	19940914	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

CN 1134669	A	19961030	CN 1994-194058	19940914	<--
CN 1103590	B	20030326			
JP 09502727	T2	19970318	JP 1995-509333	19940914	<--
JP 3081245	B2	20000828			
HU 75874	A2	19970528	HU 1996-653	19940914	<--
CZ 283207	B6	19980114	CZ 1996-2822	19940914	<--
CZ 283208	B6	19980114	CZ 1996-2823	19940914	<--
CZ 283339	B6	19980318	CZ 1996-793	19940914	<--
JP 2000239167	A2	20000905	JP 2000-71978	19940914	
JP 2000273043	A2	20001003	JP 2000-71977	19940914	
RU 2195282	C2	20021227	RU 1996-108256	19940914	
NO 9601041	A	19960514	NO 1996-1041	19960314	<--
FI 9601213	A	19960514	FI 1996-1213	19960315	<--
AU 9717709	A1	19970529	AU 1997-17709	19970403	<--
AU 706947	B2	19990701			
AU 9717710	A1	19970529	AU 1997-17710	19970403	<--
AU 9952576	A1	19991202	AU 1999-52576	19991001	<--
AU 749416	B2	20020627			
AU 750615	B2	20020725	AU 1999-59444	19991116	<--
AU 9959444	A1	20000203			
NO 2000002963	A	20000609	NO 2000-2963	20000609	
NO 2000002964	A	20000609	NO 2000-2964	20000609	
CN 1387849	A	20030101	CN 2002-121942	20020528	
CN 1387848	A	20030101	CN 2002-121943	20020528	

PRIORITY APPLN. INFO.:

US 1993-122251	B2	19930915
US 1994-292585	A	19940823
US 1994-293899		19940823
JP 1994-509333	A3	19940914
JP 1995-509333	A3	19940914
WO 1994-US10389	W	19940914
AU 1997-17709	A3	19970403

OTHER SOURCE(S): MARPAT 124:106679

AB Novel methods of using thiazolidinone derivs. and related antihyperglycemic agents to treat populations experiencing impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent **diabetes mellitus** and complications arising therefrom, are disclosed. Effects of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) was clin. tested with patients with impaired glucose tolerance by the WHO criteria; the results showed that treatment with troglitazone correlated to redn. of fasting insulin levels and return of glucose tolerance to the normal range for ~70% of the subjects.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thiazolidinedione derivs. in prevention of onset of noninsulin-dependent **diabetes**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:609143 HCAPLUS
DOCUMENT NUMBER: 123:25467
TITLE: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
AUTHOR(S): Lehmann, Juergen M.; Moore, Linda B.; Simth-Oliver, Tracey A.; Wilkison, William O.; Willson, Timothy M.; Kliewer, Steven A.
CORPORATE SOURCE: Dep. Cellular Biochem., Dep. Biochem., Dep. Med. Chem., Glaxo Res. Inst., Research Triangle Park, NC, 27709, USA
SOURCE: Journal of Biological Chemistry (**1995**), 270(22), 12953-6
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Thiazolidinedione derivs. are antidiabetic agents that increase the insulin sensitivity of target tissues in animal models of non-insulin-dependent **diabetes mellitus**. In vitro, thiazolidinediones promote adipocyte differentiation of preadipocyte and mesenchymal stem cell lines; however, the mol. basis for this adipogenic effect has remained unclear. Here, the authors report that thiazolidinediones are potent and selective activators of peroxisome proliferator-activated receptor γ(PPARγ), a member of the nuclear receptor superfamily recently shown to function in adipogenesis. The most potent

of these agents, BRL49653, binds to PPARγ with a Kd of approx. 40 nM. Treatment of pluripotent C3H10T1/2 stem cells with BRL49653 results in efficient differentiation to adipocytes. These data are the first demonstration of a high affinity PPAR ligand and provide strong evidence that PPARγ is a mol. target for the adipogenic effects of thiazolidinediones. Furthermore, these data raise the intriguing possibility that PPARγ is a target for the therapeutic actions of this class of compds.

IT **122320-73-4**, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ))

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d his

(FILE 'HOME' ENTERED AT 16:25:54 ON 28 APR 2004)

FILE 'REGISTRY' ENTERED AT 16:25:58 ON 28 APR 2004
L1 STRUCTURE UPLOADED
L2 4 S L1
L3 104 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 16:31:37 ON 28 APR 2004

```
L4          631 S L3/THU
L5          375 S L4 AND DIAB?
L6          305 S L5 AND MELLIT?
L7           57 S L6 AND PD < MAY 2000
L8           34 S L7 AND PD < MAY 1999

=> s l8 and pharmaceut?
        246616 PHARMACEUT?
L9           7 L8 AND PHARMACEUT?

=> d l9, ibib abs fhitstr, 1-7

L9   ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 1999:81575 HCAPLUS
DOCUMENT NUMBER: 130:134189
TITLE: Treatment of **diabetes** with a thiazolidinedione, an insulin secretagogue, and an α-glucosidase inhibitor
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9903478	A1	19990128	WO 1998-GB2112	19980716	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9884490	A1	19990210	AU 1998-84490	19980716	<--
EP 1001784	A1	20000524	EP 1998-935129	19980716	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810292	A	20000919	BR 1998-10292	19980716	
JP 2001510160	T2	20010731	JP 2000-502777	19980716	
ZA 9806364	A	20000117	ZA 1998-6364	19980717	<--
BG 104062	A	20001130	BG 2000-104062	20000106	
NO 2000000230	A	20000117	NO 2000-230	20000117	<--
US 2002052324	A1	20020502	US 2001-989572	20011120	
US 2003092750	A1	20030515	US 2002-322982	20021218	

PRIORITY APPLN. INFO.:

GB 1997-15298	A	19970718
WO 1998-GB2112	W	19980716
US 1999-445908	A1	19991215
US 2001-989572	B1	20011120

AB A method and compn. are disclosed for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal. The method comprises administering an effective nontoxic and **pharmaceutically** acceptable amt. of an insulin sensitizer, an insulin secretagogue and an α-glucosidase inhibitor antihyperglycemic agent

to a mammal in need thereof.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thiazolidinedione, insulin secretagogue, and α-glucosidase inhibitor for **diabetes** treatment)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:81574 HCAPLUS
DOCUMENT NUMBER: 130:134188
TITLE: Treatment of **diabetes** with a thiazolidinedione, an insulin secretagogue, and a biguanide
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9903477	A1	19990128	WO 1998-GB2110	19980716	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9884488	A1	19990210	AU 1998-84488	19980716	<--
EP 1001783	A1	20000524	EP 1998-935127	19980716	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810445	A	20000905	BR 1998-10445	19980716	
NZ 501164	A	20010629	NZ 1998-501164	19980716	
JP 2001510159	T2	20010731	JP 2000-502776	19980716	
NZ 511608	A	20021220	NZ 1998-511608	19980716	
ZA 9806363	A	20000117	ZA 1998-6363	19980717	<--
TW 505516	B	20021011	TW 1998-87111770	19980717	
NO 2000000228	A	20000117	NO 2000-228	20000117	<--
BG 104135	A	20001031	BG 2000-104135	20000207	
US 2002016287	A1	20020207	US 2001-939470	20010824	

PRIORITY APPLN. INFO.:		
GB 1997-15295	A	19970718
NZ 1998-501164	A1	19980716
WO 1998-GB2110	W	19980716
US 1999-446039	A1	19991215

AB A method and compn. are disclosed for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal. The method comprises administering an effective nontoxic and **pharmaceutically** acceptable amt. of an insulin sensitizer, an insulin secretagogue and a biguanide antihyperglycemic agent to a mammal in need thereof.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thiazolidinedione, insulin secretagogue, and biguanide for **diabetes** treatment)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:81573 HCAPLUS
DOCUMENT NUMBER: 130:134187
TITLE: Treatment of **diabetes** with insulin sensitizer thiazolidinedione and insulin secretagogue sulfonylurea
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903476	A1	19990128	WO 1998-GB2109	19980716 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9884487	A1	19990210	AU 1998-84487	19980716 <--
AU 743269	B2	20020124		
EP 998291	A1	20000510	EP 1998-935126	19980716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810904	A	20000926	BR 1998-10904	19980716
JP 2001510158	T2	20010731	JP 2000-502775	19980716
NZ 501256	A	20020927	NZ 1998-501256	19980716
NZ 515555	A	20020927	NZ 1998-515555	19980716
ZA 9806365	A	20000117	ZA 1998-6365	19980717 <--
NO 2000000229	A	20000117	NO 2000-229	20000117 <--
BG 104139	A	20001130	BG 2000-104139	20000208
US 2002045649	A1	20020418	US 2001-975883	20011012
US 2003109561	A1	20030612	US 2003-346947	20030117

PRIORITY APPLN. INFO.:	GB 1997-15306 A	19970718
	NZ 1998-501256 A1	19980716
	WO 1998-GB2109 W	19980716
	US 1999-445907 A1	19991215
	US 2001-975883 B1	20011012

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective non-toxic and **pharmaceutically** acceptable amt. of an insulin sensitizer and a sub-maximal amt. of an insulin secretagogue, to a mammal in need thereof; and a **pharmaceutical** compn. for use in such method are disclosed. The insulin secretagogue is esp. sulfonylurea. The insulin sensitizer is esp. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (I). Tablet formulations contg. I maleate are given.

IT **122320-73-4**

RL: **THU (Therapeutic use)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)

(as insulin sensitizer; treatment of **diabetes** with insulin sensitizer thiazolidinedione and insulin secretagogue sulfonylurea)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9712 HCAPLUS
DOCUMENT NUMBER: 130:61091
TITLE: Treatment of **diabetes** with thiazolidinedione and sulfonylurea
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9857649	A1	19981223	WO 1998-EP3688	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9885392	A1	19990104	AU 1998-85392	19980615	<--
EP 999845	A1	20000517	EP 1998-936363	19980615	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810142	A	20000808	BR 1998-10142	19980615	
JP 2001523270	T2	20011120	JP 1999-503754	19980615	
NZ 501163	A	20020201	NZ 1998-501163	19980615	
ZA 9805236	A	20000217	ZA 1998-5236	19980617	<--
NO 9906264	A	20000217	NO 1999-6264	19991217	<--
BG 104058	A	20001031	BG 2000-104058	20000106	
US 2001049380	A1	20011206	US 2001-848511	20010502	
US 2002147226	A1	20021010	US 2002-103326	20020321	

PRIORITY APPLN. INFO.:		
GB 1997-12854	A	19970618
GB 1998-6710	A	19980327
WO 1998-EP3688	W	19980615
US 1999-445859	B1	19991215
US 2001-848511	B1	20010502

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective nontoxic and **pharmaceutically** acceptable amt. of an insulin sensitizer and an insulin secretagogue, to a mammal in need thereof.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes** with thiazolidinedione and sulfonylurea)
RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9699 HCAPLUS
DOCUMENT NUMBER: 130:61090
TITLE: Treatment of **diabetes** with rosiglitazone and insulin
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9857636	A1	19981223	WO 1998-EP3692	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9882163	A1	19990104	AU 1998-82163	19980615	<--
EP 999837	A1	20000517	EP 1998-932169	19980615	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810444	A	20000905	BR 1998-10444	19980615	
JP 2002504138	T2	20020205	JP 1999-503757	19980615	
CN 1133431	B	20040107	CN 1998-806223	19980615	
NZ 518076	A	20040227	NZ 1998-518076	19980615	
ZA 9805237	A	20000217	ZA 1998-5237	19980617	<--
NO 9906265	A	19991217	NO 1999-6265	19991217	<--
MX 9912065	A	20000831	MX 1999-12065	19991217	
BG 104059	A	20001031	BG 2000-104059	20000106	
US 2002028768	A1	20020307	US 2001-928326	20010813	

PRIORITY APPLN. INFO.:

GB 1997-12866	A	19970618
NZ 1998-501259	A1	19980615
WO 1998-EP3692	W	19980615
US 1999-445858	B1	19991215

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective nontoxic and **pharmaceutically** acceptable amt. of insulin sensitizer rosiglitazone and insulin to a mammal in need thereof.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes mellitus** with rosiglitazone and insulin)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9698 HCAPLUS
DOCUMENT NUMBER: 130:76189
TITLE: Treatment of **diabetes** with thiazolidinedione and alpha-glucosidase inhibitor
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9857635	A1	19981223	WO 1998-EP3691	19980615	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9887999	A1	19990104	AU 1998-87999	19980615	<--
EP 975343	A1	20000202	EP 1998-939513	19980615	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
BR 9810186	A	20000808	BR 1998-10186	19980615	
JP 2001523271	T2	20011120	JP 1999-503756	19980615	
ZA 9805235	A	20000217	ZA 1998-5235	19980617	<--
NZ 501345	A	20011026	NZ 1998-501345	19980715	
NO 9906270	A	19991217	NO 1999-6270	19991217	<--
MX 9912098	A	20000831	MX 1999-12098	19991217	
US 2001034356	A1	20011025	US 2001-863136	20010523	
US 2002123514	A1	20020905	US 2002-91008	20020305	
US 2003073645	A1	20030417	US 2002-290132	20021107	

PRIORITY APPLN. INFO.:

GB 1997-12865	A	19970618
GB 1998-6708	A	19980327
WO 1998-EP3691	W	19980615
US 1999-445951	B1	19991215
US 2001-863136	B1	20010523
US 2002-91008	B1	20020305

GI



I

AB A method for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which method comprises administering an effective non-toxic and **pharmaceutically** acceptable amt. of an insulin sensitizer (I) and an α-glucosidase inhibitor antihyperglycemic agent. The effects of α-glucosidase inhibitor acarbose on the pharmacokinetics of I in healthy humans are described along with **pharmaceutical** formulations (concns. and tablets) contg. I.

IT **155141-29-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes mellitus** and conditions

assocd. with **diabetes** with thiazolidinedione deriv. and α-glucosidase inhibitors)

RN 155141-29-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:9697 HCAPLUS